Taylor & Francis Group
Browse
kccy_a_1442621_sm5094.pdf (2 MB)

Inducible CRISPR genome editing platform in naive human embryonic stem cells reveals JARID2 function in self-renewal

Download (2 MB)
Version 2 2018-11-21, 15:18
Version 1 2018-04-05, 10:56
journal contribution
posted on 2018-04-05, 10:56 authored by Amy Ferreccio, Julie Mathieu, Damien Detraux, Logeshwaran Somasundaram, Christopher Cavanaugh, Bryce Sopher, Karin Fischer, Thomas Bello, Abdiasis M. Hussein, Shiri Levy, Savannah Cook, Sonia B. Sidhu, Filippo Artoni, Nathan J. Palpant, Hans Reinecke, Yuliang Wang, Patrick Paddison, Charles Murry, Suman Jayadev, Carol Ware, Hannele Ruohola-Baker

To easily edit the genome of naïve human embryonic stem cells (hESC), we introduced a dual cassette encoding an inducible Cas9 into the AAVS1 site of naïve hESC (iCas9). The iCas9 line retained karyotypic stability, expression of pluripotency markers, differentiation potential, and stability in 5iLA and EPS pluripotency conditions. The iCas9 line induced efficient homology–directed repair (HDR) and non-homologous end joining (NHEJ) based mutations through CRISPR-Cas9 system. We utilized the iCas9 line to study the epigenetic regulator, PRC2 in early human pluripotency. The PRC2 requirement distinguishes between early pluripotency stages, however, what regulates PRC2 activity in these stages is not understood. We show reduced H3K27me3 and pluripotency markers in JARID2 2iL-I-F hESC mutants, indicating JARID2 requirement in maintenance of hESC 2iL-I-F state. These data suggest that JARID2 regulates PRC2 in 2iL-I-F state and the lack of PRC2 function in 5iLA state may be due to lack of sufficient JARID2 protein.

Funding

This work was supported by the National Institute of General Medical Sciences [grant numbers P01GM081619, R01GM097372, R01GM97372-03S1 and R01GM083867]; National Cancer Institute [grant number T32CA080416]; National Heart, Lung, and Blood Institute [grant number U01HL099997].

History